Lung cancer is one of the most frequently diagnosed cancers and is the leading cause of
cancer-related death worldwide. Non-small-cell lung cancer (NSCLC), a heterogeneous …

Background Epidermal growth factor receptor (EGFR) mutation positive (M+) non‐small cell
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …

Objective To determine the availability of data on overall survival and quality of life benefits
of cancer drugs approved in Europe. Design Retrospective cohort study. Setting Publicly …

Purpose To provide evidence-based recommendations to update the American Society of
Clinical Oncology guideline on systemic therapy for stage IV non–small-cell lung cancer …

Background The OPTIMAL study was the first study to compare efficacy and tolerability of the
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …

Background: We performed an individual patient data meta-analysis to examine the impact
of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) …

Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study,
showed that intercalated chemotherapy and erlotinib significantly prolonged progression …

The evidence base demonstrating the benefits of an early focus on palliative care for
patients with serious cancers, including advanced lung cancer, is substantial. Early …

Before the introduction of tyrosine kinase inhibitors (TKIs) for a particular subgroup of
patients, despite platinum-based combination chemotherapy, the majority of patients …

Abstract Lessons Learned The findings of this prospective, single‐arm, phase II study
showed that neoadjuvant erlotinib was well tolerated and might improve the radical …